(lp0
S'Did Navidea Biopharmaceuticals Inc  Create Value For Shareholders Over ... Simply Wall St - Mar 21, 2017 With a ROE of 23.7%, Navidea Biopharmaceuticals Inc  could hardly match the performance of its industry, which averaged a ROE of 27.45%.This Weeks Target Prices For Navidea Biopharmaceuticals, Inc.  - NewsDen'
p1
aS'Checking the Levels on Shares of Navidea Biopharmaceuticals, Inc  Benton Bulletin - 18 hours ago Navidea Biopharmaceuticals, Inc  has a current Piotroski F-Score of 5. The mission of the F-Score is to help spot companies with strengthening balance sheets, and to weed out poor performers.'
p2
aS"What We Expect Going Forward From Navidea Biopharmaceuticals Inc  Insider Financial - Oct 13, 2016 We've followed Navidea Biopharmaceuticals Inc  pretty closely over the last year or so. The company is embroiled in litigation, the outcome of which essentially could decide its future as a drugmaker, and this has weighed heavily on its&nbsp;..."
p3
aS'Navidea Biopharmaceuticals: Short-Term Pain Or Short-Term Gain? Seeking Alpha - Oct 10, 2016 Navidea  has recently been embroiled in a trench war of litigation with its loan instrument Capital Royalty Group , which starting in the first part of 2016.'
p4
aS'Investor Gauge: Looking at the Levels for Navidea Biopharmaceuticals, Inc ... BVN - 9 hours ago Looking at shares of Navidea Biopharmaceuticals, Inc , the company presently has a Gross Margin  ratio of 1.578639.'
p5
aS"Navidea Biopharmaceuticals Enters into Letter of Intent with Cardinal Health ... Yahoo Finance - Sep 6, 2016 Navidea Biopharmaceuticals, Inc.  today announced that it has executed a Letter of Intent  with Cardinal Health, Inc.  for the sale of all rights, title and interest to Navidea's Lymphoseek product for all FDA-approved ...Navidea Biopharmaceuticals Inc  Cardinal Health in deal to buy Lymphoseek from beleaguered Navidea for up to $310M - Columbus Business First"
p6
aS"Navidea Biopharmaceuticals'  CEO Michael Goldberg on Q3 2016 Results ... Seeking Alpha - Nov 3, 2016 Good morning and welcome to the Navidea Biopharmaceuticals' Third Quarter 2016 Earnings Call. My name is Carey and I will be your operator for today's call.Navidea Reports 2016 Third Quarter Financial Results - Business Wire "
p7
aS"Company Update : Navidea Biopharmaceuticals Inc's Lymphoseek(r ... Smarter Analyst - Sep 16, 2016 Navidea Biopharmaceuticals Inc  has announced that the European Medicines Agency's  Committee for Medicinal Products for Human Use  has granted a positive opinion for a new Lymphoseek 50 microgram kit for&nbsp;..."
p8
aS'Navidea Biopharmaceuticals, Inc  held by 25 SEC 13F Filers Post Analyst - Apr 17, 2017 Navidea Biopharmaceuticals, Inc  reached 82.92% versus a 1-year low price of $0.26. The stock was last seen -0.04% lower, reaching at $0.48 on 14th April.'
p9
aS'NAVIDEA BIOPHARMACEUTICALS, INC.  Files An 8-K Submission of ... Market Exclusive - Mar 2, 2017 About NAVIDEA BIOPHARMACEUTICALS, INC.  Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics.'
p10
a.